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600037, IndiaTimely restoration of infarct related artery (IRA) patency by
either pharmacological or mechanical treatment is the
primary goal of reperfusion therapy in acute myocardial
infarction (AMI). Early reperfusion improves myocardial
salvage which in turn results in superior clinical outcomes.
However, it has largely been recognized over the years that
substantial number of patients may not achieve tissue level
perfusion even after successful recanalization of the epicar-
dial coronaries. This phenomenon is famously known as
no-reflow, and has repeatedly been shown to be associated
with increased morbidity and mortality following AMI
reperfusion.1,2
Since the first demonstration of coronary occlusion as the
cause of AMI way back in 1980,3 coronary angiography has
played a pivotal role in the evaluation of coronary flow
following reperfusion either by thrombolysis or by primary
percutaneous coronary intervention (PCI). Several indices
have been developed over the past three decades as clinical
and experimental studies have providedmore insight into the
pathophysiology of coronary flow in the setting of acute
coronary syndrome (ACS). These indices have been validated
in various clinical studies and compared positively with other
modalities that assessed reperfusion in ACS. They serve as
surrogate end points of reperfusion in various clinical trials
and contributed immensely for the evaluation of new treat-
ment modalities that improve coronary perfusion.4e7 This
editorial briefly reviews various angiographic metrics used for
the assessment of reperfusion including a short discussion on
the angiographic predictors of no-reflow, and concludes with
their clinical relevance in daily clinical practice.* Corresponding author. Tel.: +91 44 26565953; fax: +91 44 26565859.
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http://dx.doi.org/10.1016/j.ihj.2012.12.021The angiographic indices are of two types: (1) Indices of
epicardial flow, (2) indices of myocardial flow, and they are
further divided into qualitative or quantitative (Table 1).1. Assessment of epicardial blood flow
1.1. TIMI flow grade
TIMI flow grade (TFG) was the first index of epicardial flow
developed by Gibson et al,8 in 1985 as a part of Thrombolysis in
Myocardial Infarction (TIMI) trial. It classifies coronary flow
into four categories (TIMI 0e3) based on the flow rate of the
contrast material in the epicardial coronary artery during
angiography. The TIMI 2 grade was later subdivided into three
subgroups (2ae2c) to further categorize the patients with slow
flow.9 TFG is a powerful tool to predict various outcomes
(mortality, reinfarction, mechanical complications, arrhyth-
mias and LV functional recovery) following reperfusion
therapy. In a meta-analysis of angiographic thrombolytic
trials involving 5498 patients, complete perfusion (TFG 3) was
associated with significantly lower mortality (3.7%) when
compared with either with partial (TFG 2) (6.1%, p < 0.0001) or
no perfusion (TFG 0e1) (9.3%, p < 0.0001).10 Moreover, fibrin
specific thrombolytics and primary PCI which could establish
TFG 3 more successfully were also associated with lesser
mortality compared to streptokinase.5 Clinical events are
related not only to establishment of IRA patency, but also to
sustained patency. This gave birth to the concept of routine
early post lysis PCI.11 The immediate availability and ease ofm (A.S. Mullasari).
y of India. All rights reserved.
Table 1 e Angiographic indices of coronary reperfusion.
Indices of epicardial flow
Qualitative
TIMI flow grade (TFG)
Quantitative
Corrected TIMI frame count (CTFC)
Indices of microvascular flow
Qualitative
Myocardial blush grading (MBG)
TIMI myocardial perfusion grading (TMPG)
Quantitative
Quantitative Blush Evaluator Score
TIMI myocardial frame count
Coronary clearance frame count
TIMI myocardial perfusion frame count
Combined
Angiographic perfusion score (APS)
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reperfusion in clinical trials of both thrombolysis and primary
PCI. It also helped in the evaluation of newer thrombolytic
agents and mechanical strategies during primary PCI to
improve reperfusion in AMI.
Eventhough TFG is a simple parameter which helps to risk
stratify AMI patients in the catheterization laboratory, it is
limited by its subjectivity and high rate of inter-observer
variability even among core laboratories. The qualitative and
categorical nature made it difficult to compare among clinical
trials.4,5
1.2. Corrected TIMI frame count (CTFC)
TIMI frame count (TFC) was the first quantitative angiographic
parameter introduced by the TIMI group in 1991. It objectively
measures the time taken by the contrast agent to reach
a standardized distal landmark by counting the number of
cine-frames. Corrected TFC (CTFC) uses a factor of 1.7 to
adjust for length in case of left anterior descending coronary
artery. The mean CTFC in normal arteries was 21.0 frames
with a standard deviation of only 3.1 frames.12 Analysis of
CTFC has givenmore insight into the pathophysiology of ACS:
(1) Flow in the IRA is slower than that in the non-IRAs and
further flow in the non-IRA in AMI patients is slower than that
in normal patients, (2) the distribution of IRA flow is unimodal,
rather than expected two peaks from slow and normal flows,
(3) IRA revascularization corrects flow in IRA to that of non-
IRA rather that to that in normal arteries, (4) CTFC in STEMI
patients is more than that in non STEMI ACS patients, (5) flow
in IRA of survivors is faster than that in nonsurvivors, (5) there
exists a subgroup of patients within TFG 3 with CTFC of <14
(TFG 4) which was associated with 0% mortality, (6) for every
10-frame rise in CTFC mortality increases by 0.7%.12,13 In
contrast to TFG, CTFC is an objective and continuous variable
with high reproducibility and excellent agreement among
core laboratories. Moreover, it provides additional prognostic
information on clinical outcomes following AMI reperfusion
both by thrombolysis and primary PCI. Despite these advan-
tages, it still remains an index of epicardial flow and does
not provide much information about the microvascular
patency.4,52. Metrics of myocardial perfusion
Pharmacological and mechanical reperfusion strategies
evolved over the past two decades have made it possible to
achieve optimal epicardial flow in more than 90% of the
patients. However, from the non-invasive imaging modalities
of myocardial perfusion it became evident that tissue level
perfusion remained poor in substantial number of patients
with TFG 3 andwere associatedwith poor acute and long-term
outcomes. This mandated the development of new angio-
graphic end points of tissue level perfusion.142.1. Qualitative
There are two important qualitative indices of myocardial
perfusion, namely, myocardial blush grading (MBG) and TIMI
myocardial perfusion grading (TMPG). Both are based on the
dynamics of themyocardial blush or ground glass appearance
during coronary angiography.
MBG was the first grading system for assessment of
microvascular perfusion developed by Van’t Hof et al14 in
1998. By comparing the intensity contrast (blush intensity) in
the infarct territory with that of unaffected ipsilateral or
contralateral territories, they divided microvascular flow into
four grades (MBG 0e3). In their study of 777 patients, MBGwas
well related to the extent of early ST-segment resolution,
enzymatic infarct size, left ventricular ejection fraction, and
importantly mortality following primary angioplasty.14 This
was further confirmed in various clinical studies involving
thousands of patients.15,16
The real world application of MBG outside the core labo-
ratories was evaluated in a study of 2118 patients who had
primary PCI in various trials, showed that operator- scored
MPG was a strong independent predictor of mortality cor-
rected for other predictive variables such as TFG. This study
showed that MPG could be applied successfully in daily
practice to predict the outcomes following primary PCI.17
TMPG was developed by TIMI group and it measures the
time for contrast medium filling and or clearance from the
myocardium. Similar to MBG, it is also graded from 0 to 3. In
a study of 762 patients in the TIMI-10B trial, the mortality was
lowest in patients with TMPG 3 (2.0%), intermediate in TMPG 2
(4.4%) and highest in TMPG 0/1 (6.0%; 3 way p ¼ 0.05). TMPG
further stratified patients with normal epicardial flow (TFG 3)
such that the 30 day mortality was lowest for TMPG 3 (0.73%),
intermediate for TMPG 2 (2.9%) and highest for TMPG 0/1
(5.0%, p ¼ 0.03 for TMPG 3 vs 0/1/2, 3 way, p ¼ 0.066). In addi-
tion, TMPG was correlated with mortality after adjusting for
TFG, CTFC, anterior wall myocardial infarction, pulse rate on
admission, female sex and age.18 Later, TMPG was validated
using quantitative assessment by digital subtraction angiog-
raphy and correlating it with ST-segment resolution in STEMI
patients. In addition, contrast dynamics were also assessed in
non-ACS patients without obstructive CAD. Comparing to
normal patients, patients with AMI had impaired microvas-
cular perfusion as evidenced by reduction in peak myocardial
contrast intensity, the rate of rise in contrast intensity, the
myocardial blush circumference and the rate of growth of
myocardial blush circumference. However, the dynamics in
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patients. This explained the remarkably low mortality in
patients with TFG 3/TMPG 3. In addition, ST-segment resolu-
tion and TMPG were significantly related.19
Ungi et al,20 directly compared the MBG and TMPG
methods in a study of 62 patients undergoing primary PCI,
and found that TMPG better correlated with enzymatic
infarct size, ST-segment resolution and left ventricular
ejection fraction (LVEF) than MPG. They concluded that the
clearance dynamics of contrast (TMPG) might be a better
method for assessing microvascular perfusion than the
densitometric method (MBG).
Though both the methods are widely used for assessing
microvascular perfusion, as with other qualitative methods,
high inter-observer variability is a major limitation of these
methods.42.2. Quantitative
To further improve upon the subjective nature of myocardial
perfusion parameters, various quantitative indices have been
developed. Digital subtraction angiography (DSA) was the
most commonly used modality to assess microvascular
perfusion. DSA was used to measure myocardial blush area
and blush intensity (MBG quantification) and speed of
myocardial blush entry and exit (TMPG quantification). New
DSA techniques like ‘moving mask’ were developed to
neutralize the cardiac movements.4
2.2.1. Quantitative Blush Evaluator Score
Haeck et al,21 proposed a computer assisted myocardial blush
quantification system e “Quantitative Blush Evaluator Score”
(QuBE) to measure myocardial perfusion in patients with
STEMI. In their study, QuBE score significantly correlated with
core lab-adjudicated myocardial blush grade, ST-segment
resolution immediately after PCI and with the post infarc-
tion CKeMB values. However, complex procedure and the off-
line nature limited its wide clinical applicability.
2.2.2. TIMI myocardial frame count
Wong et al,22 used a counting system based on cTFC to
objectively evaluate the microvascular flow dynamics in ACS
patients, by assessing the time required for the contrast to
enter the myocardium and then to reach the peak intensity.
Both the parameters were prolonged in STEMI when
compared to NSTEACS.22
2.2.3. Coronary clearance frame count
Coronary clearance frame count was introduced by Perez de
Prado et al, as a quantitative measure of myocardial blood
flow. It is an opposite index of cTFC and measures the
time required for the clearance of contrast agent from the
examined coronary artery post primary PCI. The frame in
which contrast clears from the ostium is used as frame 0 and
that in which it washes into the same coronary artery distal
landmark defined by the TIMI group was considered as the
last frame. It was positively correlated with both TMPG and
MBG (p < 0.001) and a cut-off value of 45 frames predicted
TMPG with a sensitivity of 75% and specificity of 70%.However, this method was not further validated in clinical
studies.23
2.2.4. TIMI myocardial perfusion frame count
In a further step for quantitative assessment of TMPG, Ding
et al24 proposed a new perfusion index by objectively
measuring the time interval of myocardial perfusion
dynamics. They extended cTFC which is applied for epicardial
flow assessment to the myocardial level by measuring the
time required for contrast entry into and out of micro circu-
lation. It was a quantitative and continuous index and a value
of <90 frames was defined as the cut-off for normal arteries
that does not differ for the three major epicardial coronaries
and the standard deviation was low. When they analyzed 137
STEMI patients post procedure only 52 (38%) had TMPFC of
<90. Themean TMPFCwas significantly higherwhen RCAwas
the culprit artery. Moreover, in multivariate analysis, TMPFC
was an independent predictor of both the 30 day and 6 month
MACE. TMPFC compared positively with standard indices of
epicardial (TFG and cTFC) and myocardial perfusion (TMPG
and MBG). They also assessed the reproducibility of different
perfusion parameters which showed moderate agreement for
TFG and MBG and good agreement for TMPG, CTFC, and
TMPFC.3. Combined assessment epicardial and
myocardial blood flow
3.1. Angiographic perfusion score (APS)
It has been shown in clinical studies that the epicardial flow
(TFG) both before and after primary/rescue PCI and similarly
the myocardial perfusion (TMPG) both before and after
primary/rescue PCI are associated with clinical outcomes.
With this background, Gibson et al,25 devised an additional
angiographic scoring system incorporating the above param-
eters. The APS is a 12 point scoring system which divides
patients into 3 groups: failed perfusion (0e3), partial perfusion
(4e9), and full perfusion (10e12). The APS was evaluated
initially in 877 STEMI patients from two randomized trials
in which it predicted death or myocardial infarction (failed,
16.7% [n¼ 18]; partial, 2.5% [n¼ 155]; full, 2.4% [n¼ 82]; p¼ 0.039
for trend) and SPECT infarct size (failed, median 39% [n ¼ 10];
partial, 12% [n ¼ 79]; and full, 8% [n ¼ 35]; p ¼ 0.002). In
addition, no patient with full APS died and the mortality rate
was 11.1% in patients with a failed APS (p ¼ 0.03). Similarly, in
patients who underwent late angiography and PCI following
thrombolysis in Clopidogrel as Adjunctive Reperfusion Ther-
apyeThrombolysis inMyocardial Infarction28 (CLARITYeTIMI
28) study, APS predicted mortality at 30 days and in addition,
full perfusion was associated with a lower incidence of
recurrentmyocardial infarction (MI), a composite of death and
MI, recurrent myocardial ischemia, ventricular tachyar-
rhythmia, congestive heart failure and shock (p < 0.05 for all
trends).26 Rakowski et al27 assessed the correlation between
APS andCMRparameters andN-terminal pro-brain natriuretic
peptide at 6 months. Patients with APS  10 had significantly
lower infarct size, LVvolumes, higher EF and lowerNTpro-BNP
levels.
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was evaluated in 226 patients who underwent PCI for high risk
ACS. The study included STEMI patients who had either
primary PCI or rescue PCI and NSTEMI patients who had early
or late interventions. Themain findings were APS was a better
discriminator of 30 day MACE than TMPG alone or combined
TFG and TMPG score taken only after PCI and APS predicted
low risk patients better than TMPG. This study provides
further evidence for the superiority of APS in predicting
outcomes following ACS intervention.284. Angiographic markers of no-reflow
In addition to the assessment of epicardial and microvascular
flows, angiography can also predict certain adverse features
which place the patient at high risk for distal embolization and
no-reflow following coronary intervention in ACS setting. Yip
et al,29 in their study of 794 patients who underwent primary
PCI, identified the presence of the following six angiographic
features associated with increased incidence of no-reflow: (1)
IRA occlusion with an abrupt cut-off pattern, (2) accumulated
thrombus (>5 mm) proximal to the occlusion, (3) floating
thrombus, (4) persistent contrast stasis beyond the level of
obstruction, (5) IRA reference lumen diameter  4 mm, and (6)
accumulated thrombus with the greatest linear dimension
more thanthree times theRLD inan incompletelyoccluded IRA.5. What are the clinical implications of
assessing myocardial perfusion?
The angiographic metrics have been validated in clinical trials
and also positively compared with other invasive and non-
invasive diagnostic modalities of microvascular dysfunction
in the setting of ACS. These indices have now become impor-
tant risk stratification tools in the catheterization laboratory as
they are simple, readily available at no extra cost, easy to use
with practice, and applicable to any patient undergoing inter-
vention for ACS. Moreover, the risk stratification is possible
immediately after PCI, well before the results of other prog-
nostic modalities such as ST-segment resolution, peak
biomarker values, echocardiogram assessed ejection fraction,
or cardiac magnetic resonance obtained infarct size, are
available. In addition, they further risk stratify ACS patients
over and above the clinical indices routinely used in clinical
practice and identify patientswhowill be at high risk of clinical
events following intervention, in the form of left ventricular
adverse remodeling resulting in left ventricular dysfunction
and left ventricular failure, arrhythmias, reinfarction and
mortality. Further, they also could identify subgroups of
patients with greatest potential for myocardial salvage which
could be a target for anti-no reflow medications and other
novel myocardial protective therapies. Moreover, these
patients may need close follow up to optimize the treatment
strategies in the form of medications and devices.6,19
Angiographic indices of coronary reperfusion play
a pivotal role in the assessment of prognosis following
reperfusion in the setting of ACS. With the better under-
standing of the pathology, newer markers evolved over theyears. As none of the existing parameters predict outcomes
accurately, the quest for the ideal marker will continue.
Currently, the use of combination of indices assessing both
epicardial and myocardial flows like APS might be an
attractive strategy.r e f e r e n c e s
1. Reffelmann T, Kloner RA. The “no-reflow” phenomenon:
basic science and clinical correlates. Heart. 2002;87:162e168.
2. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in
humans. J Am Coll Cardiol. 2009;54:281e292.
3. DeWood MA, Spores J, Notske R, et al. Prevalence of total
coronary occlusion during the early hours of transmural
myocardial infarction. N Engl J Med. 1980;303:897e902.
4. Pe´rez de Prado A, Ferna´ndez-Va´zquez F, Cuellas-Ramo´n JC,
Gibson CM. Coronary angiography: beyond coronary
anatomy. Rev Esp Cardiol. 2006;59:596e608.
5. Gibson CM, Scho¨mig A. Coronary and myocardial
angiography: angiographic assessment of both epicardial and
myocardial perfusion. Circulation. 2004;109:3096e3105.
6. Porto I, Hamilton-Craig C, Brancati M, et al. Angiographic
assessment of microvascular perfusionemyocardial blush in
clinical practice. Am Heart J. 2010;160:1015e1022.
7. Rind E, Arbel Y, Finkelstein A, Keren G, Banai S. Angiographic
evaluation of epicardial and microvascular coronary flow. Isr
Med Assoc J. 2009;11:173e177.
8. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase
I findings. TIMI study group. N Engl J Med. 1985;312:932e936.
9. Ellis SG, Topol EJ, George BS, et al. Recurrent ischemia
without warning. Analysis of risk factors for in-hospital
ischemic events following successful thrombolysis with
intravenous tissue plasminogen activator. Circulation.
1989;80:1159e1165.
10. Anderson JL, Karagounis LA, Califf RM. Metaanalysis of five
reported studies on the relation of early coronary patency
grades with mortality and outcomes after acute myocardial
infarction. Am J Cardiol. 1996;78:1e8.
11. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the
TIMI myocardial perfusion grades, flow grades, frame count,
and percutaneous coronary intervention to long-term
outcomes after thrombolytic administration in acute
myocardial infarction. Circulation. 2002;105:1909e1913.
12. Gibson CM, Cannon CP, Daley WL, et al. The TIMI frame
count: a quantitative method of assessing coronary artery
flow. Circulation. 1996;93:879e888.
13. Gibson CM, Murphy SA, Rizzo MJ, et al. The relationship
between the TIMI frame count and clinical outcomes after
thrombolytic administration. Circulation. 1999;99:1945e1950.
14. van’t Hof AW, Liem A, Suryapranata H, et al. Angiographic
assessment of myocardial reperfusion in patients treated
with primary angioplasty for acute myocardial infarction.
Circulation. 1998;97:2302e2306.
15. Costantini CO, Stone GW, Mehran R, et al. Frequency,
correlates, and clinical implications of myocardial perfusion
after primary angioplasty and stenting, with and without
glycoprotein IIb/IIIa inhibition, in acute myocardial
infarction. J Am Coll Cardiol. 2004;44:305e312.
16. Henriques JP, Zijlstra F, van’t Hof AW, et al. Angiographic
assessment of reperfusion in acute myocardial infarction by
myocardial blush grade. Circulation. 2003;107:2115e2119.
17. Kampinga MA, Nijsten MW, Gu YL, et al. Is the myocardial
blush grade scored by the operator during primary
percutaneous coronary intervention of prognostic value in
patients with ST-elevation myocardial infarction in
routineclinical practice? Circ Cardiovasc Interv. 2010;3:216e223.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 7e1 1 1118. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of
TIMI myocardial perfusion grade to mortality after
administration of thrombolytic drugs. Circulation.
2000;101:125e130.
19. Gibson CM, de Lemos JA, Murphy SA, et al. TIMI Study Group.
Methodologic and clinical validation of the TIMI myocardial
perfusion grade in acute myocardial infarction. J Thromb
Thrombolysis. 2002;14:233e237.
20. Ungi T, Sasi V, Ungi I, et al. Comparison of two visual
angiographic perfusion grades in acute myocardial infarction.
Ups J Med Sci. 2009;114:149e153.
21. Haeck JD, Gu YL, Vogelzang M, et al. Feasibility and
applicability of computer-assisted myocardial blush
quantification after primary percutaneous coronary
intervention for ST-segment elevation myocardial infarction.
Catheter Cardiovasc Interv. 2010;75:701e706.
22. Wong GC, Frisch D, Murphy SA, et al. LIMIT AMI and
TACTICS-TIMI 18 Study Groups. Time for contrast
material to traverse the epicardial artery and the
myocardium in ST-segment elevation acute myocardial
infarction versus unstable angina pectoris/non-ST-elevation
acute myocardial infarction. Am J Cardiol.
2003;91:1163e1167.
23. de Prado AP, Ferna´ndez-Va´zquez F, Carlos Cuellas-Ramon J,
Iglesias-Garriz I. Coronary clearance frame count: a new
index of microvascular perfusion. J Thromb Thrombolysis.
2005;19:97e100.24. Ding S, Pu J, Qiao ZQ, et al. TIMI myocardial perfusion frame
count: a new method to assess myocardial perfusion and its
predictive value for short-term prognosis. Catheter Cardiovasc
Interv. 2010;75:722e732.
25. Gibson CM, Murphy SA, Morrow DA, et al. Angiographic
perfusion score: an angiographic variable that integrates both
epicardial and tissue level perfusion before and after
facilitated percutaneous coronary intervention in acute
myocardial infarction. Am Heart J. 2004;148:336e340.
26. Pride YB, Buros JL, Lord E, et al. TIMI Study Group. Angiographic
perfusion score in patients treatedwith PCI at late angiography
following fibrinolytic administration for ST-segment elevation
myocardial infarction is associated with morbidity and
mortality at 30 days. J Thromb Thrombolysis. 2008;26:106e112.
27. Rakowski T, Legutko J, Kleczynski P, et al. Angiographic
perfusion score assessed in patients with acute myocardial
infarction is correlated with cardiac magnetic resonance
infarct size and N-terminal pro-brain natriuretic peptide in
6-month follow-up. J Thromb Thrombolysis. 2010;30:441e445.
28. Narain VS, Fischer L, Puri A, Sethi R, Dwivedi SK. Prognostic
value of Angiographic Perfusion Score (APS) percutaneous
interventions in acute coronary syndromes. Indian Heart J.
2013;65:1e6.
29. Yip HK, Chen MC, Chang HW, et al. Angiographic
morphologic features of infarct-related arteries and timely
reperfusion in acutemyocardial infarction: predictors of slow-
flow and no-reflow phenomenon. Chest. 2002;122:1322e1332.
